Cannabis-involvement in emergency department visits for self-harm following medical and non-medical cannabis legalization

被引:0
|
作者
Myran, Daniel T. [1 ,2 ,3 ,5 ,12 ]
Gaudreault, Adrienne [2 ]
Pugliese, Michael [4 ]
Tanuseputro, Peter [1 ,2 ,3 ,4 ,5 ]
Saunders, Natasha [6 ,7 ,8 ,9 ,10 ,11 ]
机构
[1] Bruye re Res Inst, Ottawa, ON, Canada
[2] Ottawa Hosp Res Inst, Clin Epidemiol Program, Ottawa, ON, Canada
[3] Univ Ottawa, Dept Family Med, Ottawa, ON, Canada
[4] Ottawa Hosp Res Inst, ICES uOttawa, Ottawa, ON, Canada
[5] Univ Ottawa, Sch Epidemiol & Publ Hlth, Ottawa, ON, Canada
[6] Hosp Sick Children, Toronto, ON, Canada
[7] Univ Toronto, Dept Pediat, Toronto, ON, Canada
[8] ICES, Toronto, ON, Canada
[9] SickKids Res Inst, Child Hlth Evaluat Sci, Toronto, ON, Canada
[10] Univ Toronto, Inst Hlth Policy Management & Evaluat, Toronto, ON, Canada
[11] Univ Toronto, Edwin SH Leong Ctr Hlth Children, Toronto, ON, Canada
[12] Hosp Res Inst, Clin Epidemiol Program, 1053 Carling Ave, POB 693, Ottawa, ON K1Y 4E9, Canada
基金
加拿大健康研究院;
关键词
D O I
10.1016/j.jad.2024.01.264
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Aims: Cannabis use may increase the risk of self-harm, but whether legalization of cannabis is associated with changes in self-harm is unknown. We examined changes in cannabis-involvement in emergency department (ED) visits for self-harm after the liberalization of medical and legalization of non-medical cannabis in Canada. Methods: This repeated cross-sectional study used health administrative data to identify all ED visits for self-harm in individuals aged ten and older between January 2010 and December 2021. We identified self-harm ED visits with a co-diagnosis of cannabis (main exposure) or alcohol (control condition) and examined changes in rates of visits over four distinct policy periods (pre-legalization, medical liberalization, non-medical legalization with restrictions, and non-medical commercialization/COVID-19) using Poisson models. Results: The study included 158,912 individuals with one or more self-harm ED visits, of which 7810 (4.9 %) individuals had a co-diagnosis of cannabis use and 24,761 (15.6 %) had a co-diagnosis of alcohol use. Between 2010 and 2021, the annual rate of ED visits for self-harm injuries involving cannabis per 100,000 individuals increased by 90.1 % (3.6 in 2010 to 6.9 in 2021 per 100,000 individuals), while the annual rate of self-harm injuries involving alcohol decreased by 17.3 % (168.1 in 2010 to 153.1 in 2021 per 100,000 individuals). The entire increase in visits relative to pre-legalization occurred after medical liberalization (seasonally adjusted Risk Ratio [asRR] 1.71 95 % CI 1.09-1.15) with no further increases during the legalization with restrictions (asRR 1.77 95%CI 1.62-1.93) or commercialization/COVID-19 periods (asRR 1.63 95%CI 1.50-176). Conclusions: Cannabis-involvement in self-harm ED visits almost doubled over 12 years and may have accelerated after medical cannabis liberalization. While the results cannot determine whether cannabis is increasingly causing self-harm ED visits or whether cannabis is increasingly being used by individuals at high risk of self-harm, greater detection for cannabis use in this population and intervention may be indicated.
引用
收藏
页码:853 / 862
页数:10
相关论文
共 50 条
  • [1] Association between non-medical cannabis legalization and emergency department visits for cannabis-induced psychosis
    Myran, Daniel T.
    Pugliese, Michael
    Roberts, Rhiannon L.
    Solmi, Marco
    Perlman, Christopher M.
    Fiedorowicz, Jess
    Tanuseputro, Peter
    Anderson, Kelly K.
    MOLECULAR PSYCHIATRY, 2023, 28 (10) : 4251 - 4260
  • [2] Association between non-medical cannabis legalization and emergency department visits for cannabis-induced psychosis
    Daniel T. Myran
    Michael Pugliese
    Rhiannon L. Roberts
    Marco Solmi
    Christopher M. Perlman
    Jess Fiedorowicz
    Peter Tanuseputro
    Kelly K. Anderson
    Molecular Psychiatry, 2023, 28 : 4251 - 4260
  • [3] Priorities for addressing adolescent cannabis consumption following non-medical cannabis legalization in Canada
    Imtiaz, Sameer
    Elton-Marshall, Tara
    Hamilton, Hayley A.
    Rueda, Sergio
    Rehm, Juergen
    LANCET REGIONAL HEALTH-AMERICAS, 2024, 35
  • [4] Cannabis knowledge and implications for health: Considerations regarding the legalization of non-medical cannabis
    Zamengo, Luca
    Frison, Giampietro
    Zwitser, Guus
    Salomone, Alberto
    Freeman, Tom P.
    MEDICINE SCIENCE AND THE LAW, 2020, 60 (04) : 309 - 314
  • [5] Considering the health and social welfare impacts of non-medical cannabis legalization
    Fischer, Benedikt
    Bullen, Chris
    Elder, Hinemoa
    Fidalgo, Thiago M.
    WORLD PSYCHIATRY, 2020, 19 (02) : 187 - 188
  • [6] Emergency Department Pediatric Visits in Alberta for Cannabis After Legalization
    Yeung, Matthew E. M.
    Weaver, Colin G.
    Hartmann, Riley
    Haines-Saah, Rebecca
    Lang, Eddy
    PEDIATRICS, 2021, 148 (04)
  • [7] The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients
    Philippe Lucas
    Susan Boyd
    M.-J. Milloy
    Zach Walsh
    Journal of Cannabis Research, 3
  • [8] The impact of non-medical cannabis legalization and other exposures on retention in longitudinal cannabis research: a survival analysis of a prospective study of Canadian medical cannabis patients
    Lucas, Philippe
    Boyd, Susan
    Milloy, M. -J.
    Walsh, Zach
    JOURNAL OF CANNABIS RESEARCH, 2021, 3 (01)
  • [9] Changes in Emergency Department Visits for Cannabis Hyperemesis Syndrome Following Recreational Cannabis Legalization and Subsequent Commercialization in Ontario, Canada
    Myran, Daniel Thomas
    Roberts, Rhiannon
    Pugliese, Michael
    Taljaard, Monica
    Tanuseputro, Peter
    Pacula, Rosalie Liccardo
    JAMA NETWORK OPEN, 2022, 5 (09) : E2231937
  • [10] The Legalization Debate of non-medical cannabis Consumption DGPPN- Position Paper
    Havemann-Reinecke, U.
    Hoch, E.
    Preuss, U. W.
    Kiefer, F.
    Batra, A.
    Gerlinger, G.
    Hauth, I.
    NERVENARZT, 2017, 88 (03): : 291 - 298